Lazarovits, J.; Epelbaum, R.; Lachter, J.; Amikam, Y.; Ben Arie, J.
Multisite Is Superior to Single-Site Intratumoral Chemotherapy to Retard the Outcomes of Pancreatic Ductal Adenocarcinoma in a Murine Model. Cancers 2023, 15, 5801.
https://doi.org/10.3390/cancers15245801
AMA Style
Lazarovits J, Epelbaum R, Lachter J, Amikam Y, Ben Arie J.
Multisite Is Superior to Single-Site Intratumoral Chemotherapy to Retard the Outcomes of Pancreatic Ductal Adenocarcinoma in a Murine Model. Cancers. 2023; 15(24):5801.
https://doi.org/10.3390/cancers15245801
Chicago/Turabian Style
Lazarovits, Janette, Ron Epelbaum, Jesse Lachter, Yaron Amikam, and Jacob Ben Arie.
2023. "Multisite Is Superior to Single-Site Intratumoral Chemotherapy to Retard the Outcomes of Pancreatic Ductal Adenocarcinoma in a Murine Model" Cancers 15, no. 24: 5801.
https://doi.org/10.3390/cancers15245801
APA Style
Lazarovits, J., Epelbaum, R., Lachter, J., Amikam, Y., & Ben Arie, J.
(2023). Multisite Is Superior to Single-Site Intratumoral Chemotherapy to Retard the Outcomes of Pancreatic Ductal Adenocarcinoma in a Murine Model. Cancers, 15(24), 5801.
https://doi.org/10.3390/cancers15245801